Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 173
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Anticancer Drugs ; 2024 Jun 26.
Artículo en Inglés | MEDLINE | ID: mdl-38924456

RESUMEN

Human epidermal growth factor receptor 2 (HER2) is a transmembrane glycoprotein receptor with intracellular tyrosine kinase activity. It is generally considered as a poor prognostic marker. Targeted therapies, such as small molecule tyrosine kinase inhibitors (TKIs), showed limited efficacy in HER2-mutant advanced nonsmall cell lung cancer (NSCLC). In the 2023 National Comprehensive Cancer Network guidelines for NSCLC, antibody-drug conjugate trastuzumab emtansine is recommended for the treatment of HER2-mutant lung cancer. However, this medication is currently not approved in certain regions.So it is necessary to explore alternative treatment options for HER2-mutant NSCLC patients. In our study of a patient with HER2 exon 20 insertion lung adenocarcinoma who had previously failed multiple epidermal growth factor receptor (EGFR)-TKI treatments, we discovered that sunvozertinib could stabilize the patient's condition, achieving a progression-free survival of 87 days. This is a novel finding that may provide new treatment options for HER2 exon 20 insertion patients who have failed TKI therapy.

2.
Cancer Immunol Immunother ; 72(7): 2257-2265, 2023 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-36871274

RESUMEN

BACKGROUND: Camrelizumab has shown encouraging efficacy in advanced non-small cell lung cancer (NSCLC), either as monotherapy or combined with chemotherapy. However, evidence of neoadjuvant camrelizumab for NSCLC remains lacking. METHODS: Patients with NSCLC treated with neoadjuvant camrelizumab-based therapy followed by surgery between December 2020 and September 2021 were retrospectively reviewed. Demographic and clinical data, details of neoadjuvant therapy and surgical information were retrieved. RESULTS: In this multicenter retrospective real-world study, 96 patients were included. Ninety-five patients (99.0%) received neoadjuvant camrelizumab combined with platinum-based chemotherapy, with a median of 2 cycles (range 1-6). The median interval from the last dose to surgery was 33 days (range 13-102 days). Seventy patients (72.9%) underwent minimally invasive surgery. Lobectomy was the most frequent surgical procedure (94 [97.9%]). The median estimated intraoperative blood loss was 100 mL (range 5-1200 mL), and the median operative time was 3.0 h (range 1.5-6.5 h). The R0 resection rate was 93.8%. Twenty-one patients (21.9%) experienced postoperative complications, with the most common being cough and pain (both 6 [6.3%]). The overall response rate was 77.1% (95% CI 67.4-85.0%), and the disease control rate was 93.8% (95% CI 86.9-97.7%). Twenty-six patients (27.1%, 95% CI 18.5-37.1%) had pathological complete response. Neoadjuvant treatment-related adverse events of grade ≥ 3 were reported in seven patients (7.3%), with the most frequent being abnormal liver enzymes (two [2.1%]). No treatment-related deaths were reported. CONCLUSION: The real-world data indicated that camrelizumab-based therapy had promising efficacy for NSCLC in the neoadjuvant setting, with manageable toxicities. Prospective studies investigating neoadjuvant camrelizumab are warranted.


Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas , Neoplasias Pulmonares , Humanos , Terapia Neoadyuvante , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Estudios Retrospectivos , Estudios Prospectivos , Neoplasias Pulmonares/tratamiento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico
3.
Drug Metab Dispos ; 51(12): 1583-1590, 2023 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-37775332

RESUMEN

To investigate the value of drug exposure and host germline genetic factors in predicting apatinib (APA)-related toxicities. METHOD: In this prospective study, plasma APA concentrations were quantified using liquid chromatography with tandem mass spectrometry, and 57 germline mutations were genotyped in 126 advanced solid tumor patients receiving 250 mg daily APA, a vascular endothelial growth factor receptor II inhibitor. The correlation between drug exposure, genetic factors, and the toxicity profile was analyzed. RESULTS: Non-small cell lung cancer (NSCLC) was more prone to APA-related toxicities and plasma concentrations of APA, and its main metabolite M1-1 could be associated with high-grade adverse events (AEs) (P < 0.01; M1-1, P < 0.01) and high-grade antiangiogenetic toxicities (APA, P = 0.034; P < 0.05), including hypertension, proteinuria, and hand-foot syndrome, in the subgroup of NSCLC. Besides, CYP2C9 rs34532201 TT carriers tended to have higher levels of APA (P < 0.001) and M1-1 (P < 0.01), whereas CYP2C9 rs1936968 GG carriers were predisposed to higher levels of M1-1 (P < 0.01). CONCLUSION: Plasma APA and M1-1 exposures were able to predict severe AEs in NSCLC patients. Dose optimization and drug exposure monitoring might need consideration in NSCLC patients with CYP2C9 rs34532201 TT and rs1936968 GG. SIGNIFICANCE STATEMENT: Apatinib is an anti-VEGFR2 inhibitor for the treatment of multiple cancers. Though substantial in response, apatinib-induced toxicity has been a critical issue that is worth clinical surveillance. Few data on the role of drug exposure and genetic factors in apatinib-induced toxicity are available. Our study demonstrated a distinct drug-exposure relationship in NSCLC but not other tumors and provided invaluable evidence of drug exposure levels and single nucleotide polymorphisms as predictive biomarkers in apatinib-induced severe toxicities.


Asunto(s)
Antineoplásicos , Carcinoma de Pulmón de Células no Pequeñas , Neoplasias Pulmonares , Humanos , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Carcinoma de Pulmón de Células no Pequeñas/genética , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Pulmonares/genética , Polimorfismo de Nucleótido Simple , Antineoplásicos/efectos adversos , Estudios Prospectivos , Factor A de Crecimiento Endotelial Vascular/uso terapéutico , Citocromo P-450 CYP2C9
4.
BMC Cancer ; 23(1): 686, 2023 Jul 21.
Artículo en Inglés | MEDLINE | ID: mdl-37479966

RESUMEN

BACKGROUND: SETD2 protects against genomic instability via maintenance of homologous recombination repair (HRR) and mismatch repair (MMR) in neoplastic cells. However, it remains unclear whether SETD2 dysfunction is a complementary or independent factor to microsatellite instability-high (MSI-H) and tumor mutational burden-high (TMB-H) for immunocheckpoint inhibitor (ICI) treatment, and little is known regarding whether this type of dysfunction acts differently in various types of cancer. METHODS: This cohort study used multidimensional genomic data of 6726 sequencing samples from our cooperative and non-public GenePlus institute from April 1 through April 10, 2020. MSIsensor score, HRD score, RNAseq, mutational data, and corresponding clinical data were obtained from the TCGA and MSKCC cohort for seven solid tumor types. RESULTS: A total of 1021 genes underwent target panel sequencing reveal that SETD2 mutations were associated with a higher TMB. SETD2 deleterious mutation dysfunction affected ICI treatment prognosis independently of TMB-H (p < 0.01) and had a lower death hazard than TMB-H in pancancer patients (0.511 vs 0.757). Significantly higher MSI and lower homologous recombination deficiency were observed in the SETD2 deleterious mutation group. Improved survival rate was found in the MSKCC-IO cohort (P < 0.0001) and was further confirmed in our Chinese cohort. CONCLUSION: We found that SETD2 dysfunction affects ICI treatment prognosis independently of TMB-H and has a lower death hazard than TMB-H in pancancer patients. Therefore, SETD2 has the potential to serve as a candidate biomarker for ICI treatment. Additionally, SETD2 should be considered when dMMR is detected by immunohistochemistry.


Asunto(s)
Reparación del ADN , Inestabilidad de Microsatélites , Neoplasias Pancreáticas , Humanos , Pueblo Asiatico , Estudios de Cohortes , Reparación de la Incompatibilidad de ADN/genética , Reparación del ADN/genética , Inestabilidad Genómica , Inmunoterapia , Mutación , Neoplasias Pancreáticas/genética , Neoplasias Pancreáticas/mortalidad , Reparación del ADN por Recombinación/genética
5.
Anticancer Drugs ; 34(9): 1058-1064, 2023 10 01.
Artículo en Inglés | MEDLINE | ID: mdl-37265026

RESUMEN

Rearranged during transfection ( RET ) fusions and epidermal growth factor receptor ( EGFR ) mutations are potent oncogenic drivers in patients with nonsmall cell lung cancer (NSCLC), but rarely co-exist. Concurrent RET/EGFR mutations have been reported in patients with NSCLC who develop resistance to EGFR tyrosine kinase inhibitors but are even less frequent in treatment-naïve patients. Consequently, there is no standard treatment for RET/EGFR -mutated NSCLC. We report a case of RET/EGFR mutant NSCLC successfully treated with the oral, potent, highly selective RET inhibitor selpercatinib (160 mg daily for 28-day cycles) in an ongoing phase II study in Chinese patients with NSCLC (LIBRETTO-321). The patient, a female nonsmoker, was diagnosed with de-novo left lung adenocarcinoma with neuroendocrine differentiation, and a RET fusion was detected by next-generation sequencing testing. The patient had two tumors in the pleura, a third in the subcarinal lymph node, and a nontarget tumor in the pleura. Pleural biopsy analysis confirmed a RET fusion KIF5B (K15;R12) and an EGFR exon 19 deletion. The patient achieved a partial response (PR) with selpercatinib (absence of target tumors in pleura and reduction in the size of lymph node tumor). The PR persisted for 14.7 months, with disease progression in the nontarget lesion in the pleura and a new lesion in the liver (the PR had persisted), resulting in the discontinuation of selpercatinib. The only notable adverse event was grade 3 elevated transaminase, that was effectively managed by dose reduction. These data may support the use of selpercatinib in patients with RET/EGFR co-mutated NSCLC.


Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas , Neoplasias Pulmonares , Femenino , Humanos , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Carcinoma de Pulmón de Células no Pequeñas/genética , Carcinoma de Pulmón de Células no Pequeñas/patología , Pueblos del Este de Asia , Receptores ErbB/genética , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/patología , Mutación , Inhibidores de Proteínas Quinasas , Proteínas Proto-Oncogénicas c-ret/genética , Proteínas Proto-Oncogénicas c-ret/metabolismo , Ensayos Clínicos Fase II como Asunto
6.
Environ Res ; 218: 115010, 2023 02 01.
Artículo en Inglés | MEDLINE | ID: mdl-36502911

RESUMEN

To realize water and resource recovery from anaerobically digested manure centrate, the effect of combined coagulation and membrane treatment on contaminant residuals and membrane fouling was investigated. Two combined treatments were used to explore the properties of the retention of nutrients and the removal of risk pollutants. Behaviors and reversibility of membrane fouling after combined treatment were also examined. The result showed that the combined treatment significantly improved the water recovery rate by more than 60% and achieved better nutrient enrichment. Meanwhile, the combined treatment had certain removal effects on heavy metals and antibiotics, which promoted the safety of farmland utilization of anaerobically digested manure centrate. Moreover, the combined treatment reduced the membrane fouling by removing most suspended solids in the digested centrate. Combined coagulation and membrane treatment show great potential for practical applications in the treatment of anaerobically digested manure centrate due to the easy operation and excellent effect. This work provides a technical reference for the harmless and resource recovery of anaerobically digested manure centrate.


Asunto(s)
Estiércol , Metales Pesados , Nutrientes , Agua
7.
Immunopharmacol Immunotoxicol ; 45(6): 780-787, 2023 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-37339370

RESUMEN

Neuromuscular associated respiratory failure is a rare toxicity of immunotherapy for malignant tumors. In most cases, it may overlap with the symptoms of the primary disease or myocarditis, myositis and myasthenia gravis, resulting in difficult etiological diagnosis. Early detection and optimal treatment are still topics that need attention. Here, a case of 51-year-old male lung cancer patient with sintilimab-associated myasthenia gravis, myositis, and myocarditis overlap syndrome involving the diaphragm who developed severe type II respiratory failure was reported. After high-dose methylprednisolone, immunoglobulin and pyridostigmine intravenous injection with non-invasive positive pressure ventilation, the patient's symptoms improved significantly and was discharged. One year later, the patient received immunotherapy again due to tumor progression. After 53 days, he developed dyspnea again. Chest X-ray demonstrated marked elevation of the diaphragm, and the electromyogram demonstrated dysfunction of diaphragm. With rapid diagnosis and timely treatment, the patient was finally discharged safely. A comprehensive search of PubMed, EMBASE was performed to identify all previously reported cases of immune checkpoint inhibitors-associated respiratory failure. The potential mechanisms of respiratory failure caused by ICI-associated diaphragmatic dysfunction may be related to T cell-mediated immune disturbances and we proposed possible diagnostic processes. For patients with unexplained respiratory failure who are receiving immunotherapy, standardized diagnostic strategies should be implemented immediately on admission before deciding whether to conduct a more invasive diagnostic procedure or empirical treatment.


Asunto(s)
Antineoplásicos Inmunológicos , Neoplasias Pulmonares , Miastenia Gravis , Miocarditis , Miositis , Insuficiencia Respiratoria , Masculino , Humanos , Persona de Mediana Edad , Inhibidores de Puntos de Control Inmunológico/efectos adversos , Antineoplásicos Inmunológicos/uso terapéutico , Miocarditis/inducido químicamente , Miocarditis/tratamiento farmacológico , Neoplasias Pulmonares/tratamiento farmacológico , Miastenia Gravis/diagnóstico , Miastenia Gravis/tratamiento farmacológico , Miositis/inducido químicamente , Miositis/tratamiento farmacológico , Miositis/patología , Insuficiencia Respiratoria/inducido químicamente , Insuficiencia Respiratoria/terapia
8.
Respir Res ; 23(1): 175, 2022 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-35778703

RESUMEN

BACKGROUND: Sputum biopsies offer unique advantages such as non-invasiveness and convenient collection. The one investigation so far on sputum for genome profiling in advanced non-small cell lung cancer (aNSCLC) suggested promising performance. However, it remains undefined whether clinicohistologic characteristics were associated with performance and how this knowledge could help guide choice of liquid biopsy. METHODS: Targeted sequencing with a 520-gene panel was performed on prospectively collected matched tumor tissue (TIS), plasma (PLA), and sputum supernatant (SPU) from 71 aNSCLC patients (NCT05034445). Genomic alteration detection was characterized in a series of aspects and interrogated for association with 14 clinicohistologic features. Nomograms were constructed with logistic regression for predicting the liquid biopsy type with greater sensitivity. RESULTS: Compared with PLA, SPU showed comparable quality control metrics, mutation detection rate (SPU: 67.6%, PLA: 70.4%), concordance with tumor tissue (67.6% vs. 73.2%), and correlation with tissue-based tumor mutation burden levels (r = 0.92 vs. 0.94). For driver alterations, detection was less sensitive with SPU (50.0%) than PLA (63.5%) in the entire cohort but similarly or more sensitive in patients with centrally located lung tumors or smoking history or for altered ALK or KRAS. Two nomograms were constructed and enabled predicting the probability of superior sensitivity with SPU with moderate to borderline high accuracy. CONCLUSION: In addition to demonstrating comparable performance in multiple aspects, this study is the first to propose nomograms for choosing liquid biopsy based on clinicohistologic characteristics. Future research is warranted to delineate the clinical utility of sputum for genome profiling.


Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas , Neoplasias Pulmonares , Carcinoma de Pulmón de Células no Pequeñas/diagnóstico , Carcinoma de Pulmón de Células no Pequeñas/genética , Carcinoma de Pulmón de Células no Pequeñas/patología , Estudios Clínicos como Asunto , Humanos , Biopsia Líquida , Neoplasias Pulmonares/diagnóstico , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/patología , Poliésteres , Esputo
9.
Anticancer Drugs ; 33(9): 963-965, 2022 10 01.
Artículo en Inglés | MEDLINE | ID: mdl-36136993

RESUMEN

Heterogeneity in the acquired genetic cause of osimertinib resistance leads to difficulties in understanding and addressing molecular mechanisms of resistance in clinical practice. Recent studies and clinical cases established that altered BRAF could drive osimertinib resistance in an EGFR-independent manner. Herein, we present a case in which an EGFR-positive, MET-amplified nonsmall cell lung cancer (NSCLC) patient acquired BRAF p.D594N mutation on third-line osimertinib plus crizotinib and responded to seventh-line treatment with osimertinib plus MEK inhibitor trametinib. Disease control was maintained for 6 months. BRAF p.D594N is a kinase impaired mutation but leads to increased MEK/ERK signaling, which could activate the downstream signaling of EGFR and induce drug resistance. There has been preclinical evidence supporting dual inhibition of MEK and EGFR for overcoming this resistance. To the best of our knowledge, our case is the first to provide clinical evidence that trametinib plus osimertinib was effective for EGFR-mutant NSCLC patients with acquired BRAF p.D594N mutation. More supporting data and systematic validation studies are needed for comprehensive understanding of this therapy strategy and future applications.


Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas , Fibrosarcoma , Neoplasias Pulmonares , Acrilamidas , Compuestos de Anilina , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Carcinoma de Pulmón de Células no Pequeñas/genética , Crizotinib/farmacología , Resistencia a Antineoplásicos/genética , Receptores ErbB/genética , Fibrosarcoma/tratamiento farmacológico , Humanos , Indoles , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Pulmonares/genética , Quinasas de Proteína Quinasa Activadas por Mitógenos , Mutación , Inhibidores de Proteínas Quinasas/farmacología , Proteínas Proto-Oncogénicas B-raf/genética , Piridonas , Pirimidinas , Pirimidinonas
10.
J Environ Manage ; 321: 115971, 2022 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-36104883

RESUMEN

The activated peroxymonosulfate (PMS) process has been widely applied for degrading organic pollutants. However, its application is limited by low metal cycling, and the contribution of oxygen species remains unclear. Here, the crystal structure, surface morphology, and elemental valence of the synthesized manganese ferrite (MnFe2O4) catalyst were investigated by SEM, HRTEM, XRD, and XPS. A novel MnFe2O4/PMS/ascorbic acid (AA) system was constructed to enhance the Fe/Mn cycling on the surfaces of the MnFe2O4 catalyst. The addition of AA can significantly increase the decomposition of organic pollutants, and the apparent rate constant of the MnFe2O4/PMS/AA system is 8.2 times higher than that of MnFe2O4/PMS. AA facilitates the reduction of Fe/Mn(III) and the dissolution of Fe/Mn(II), creating a Fe/Mn cycle between the heterogeneous and homogeneous interfaces of the catalyst. Furthermore, AA greatly increases the activity of adsorbed oxygen on the catalyst surfaces, generating a large amount of singlet oxygen (1O2), which contributes significantly to the destruction of organic pollutants. The efficient, fast, and environmentally friendly PMS activation method in this study can provide reliable technical support for treating refractory organic pollutants in water.


Asunto(s)
Contaminantes Ambientales , Oxígeno Singlete , Ácido Ascórbico , Oxígeno , Peróxidos
11.
J Environ Manage ; 308: 114615, 2022 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-35131709

RESUMEN

The dual-chamber photoelectrocatalytic (PEC) system possess advantages in the degradation efficiency and processing cost of organic contaminants. In this study, TiO2 nanotube arrays modified by rGO and g-C3N4 (rGO/g-C3N4/TNAs) photoelectrodes were successfully prepared. The surface micromorphology, chemical structure, crystal structure, and basic element composition of rGO/g-C3N4/TNAs photoelectrodes were studied by SEM, FTIR, XRD, Raman, and XPS. UV-vis absorption, photoluminescence (PL) spectra, and photoelectrochemical (PECH) tests were used to explore the photoelectrochemical characteristics of rGO/g-C3N4/TNAs photoelectrodes. Under simulated sunlight illumination, the dual-chamber PEC system with external bias voltage was used to investigate the degradation of oxytetracycline (OTC) on rGO/g-C3N4/TNAs photoelectrodes. The results showed that rGO and g-C3N4 were successfully loaded on TNAs, and the separation efficiency of electrons and holes at rGO/g-C3N4/TNAs photoelectrodes was improved. The light absorption range of rGO/g-C3N4/TNAs photoelectrodes extends to the visible light region and has better light absorption performance. Compared with the photocatalytic process, when 1.2 V bias voltage was applied, the degradation efficiency of OTC in anode and cathode chambers in PEC were increased by 3.28% and 44.01% within 60 min, respectively. In addition, the anode and cathode chambers have different degradation effects on OTC. Both the external bias voltage and initial pH have significant effects in cathode chamber, but have little effect in photoanode chamber. The fluorescence excitation-emission matrix spectra and liquid chromatography-tandem mass spectrometry showed that there were different intermediates in the degradation process of OTC. This study indicated that for the dual-chamber PEC system, rGO/g-C3N4/TNAs photoelectrodes exhibited excellent photocatalytic performance and have potential application prospects in water environmental remediation.


Asunto(s)
Grafito , Oxitetraciclina , Catálisis , Galvanoplastia , Grafito/química
12.
Mod Pathol ; 33(4): 626-638, 2020 04.
Artículo en Inglés | MEDLINE | ID: mdl-31659278

RESUMEN

To understand the molecular mechanism of tumorigenesis of pulmonary lymphoepithelioma-like carcinoma and explore potential therapeutic strategies, we investigated the genomic profiles and PD-L1 expression of 29 Chinese pulmonary lymphoepithelioma-like carcinoma patients at various stages. We performed capture-based targeted sequencing on tissue samples collected from 27 patients with sufficient samples using a panel consisting of 520 cancer-related genes, spanning 1.64 Mb of the human genome. We identified 184 somatic mutations in 109 genes from 26 patients. One patient had no mutations detected by this panel. Copy number variations were detected in 52% (14/27) of the patients, with a majority having advanced-stage disease (10/14). Except for the detection of ERBB2 amplification and KRAS mutation in two patients, no other classic lung cancer driver mutations were detected. Interestingly, 78% (21/27) of the patients had mutations in epigenetic regulators. Of the 184 mutations identified, 51 occurred in 29 epigenetics-related genes. Furthermore, we performed PD-L1 immunohistochemistry staining using the Dako 22C3 assay and demonstrated that 69% (20/29) of the cohort had positive PD-L1 expression, of which three patients received and benefited from a PD-1 inhibitor. In conclusion, we elucidated a distinct genomic landscape associated with pulmonary lymphoepithelioma-like carcinoma with no classic lung cancer driver mutation but an enrichment of mutations in epigenetic regulators. The detection of high PD-L1 expression and lack of any canonical druggable driver mutations raises the potential of checkpoint immunotherapy for pulmonary lymphoepithelioma-like carcinoma.


Asunto(s)
Antígeno B7-H1/análisis , Biomarcadores de Tumor/análisis , Biomarcadores de Tumor/genética , Carcinoma de Pulmón de Células no Pequeñas/genética , Carcinoma de Pulmón de Células no Pequeñas/inmunología , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/inmunología , Transcriptoma , Adulto , Anciano , Antígeno B7-H1/antagonistas & inhibidores , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , China , Epigénesis Genética , Femenino , Amplificación de Genes , Dosificación de Gen , Predisposición Genética a la Enfermedad , Humanos , Inhibidores de Puntos de Control Inmunológico/uso terapéutico , Neoplasias Pulmonares/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Mutación , Fenotipo , Resultado del Tratamiento , Adulto Joven
13.
Chem Eng J ; 3942020 Aug 15.
Artículo en Inglés | MEDLINE | ID: mdl-33414675

RESUMEN

Three novel persulfate activators, Fe(II)-based metal-organic frameworks (MOFs) were synthesized for the degradation of sulfamethoxazole (SMX). The degradation experiment results showed that all the Fe(II)MOFs could effectively activate persulfate and degrade more than 97% SMX within 180 min, with higher than 77% persulfate decomposition efficiencies. It was found by Mössbauer spectra that the variation of organic ligands for synthesis have an influence on the content of Fe(II) of these MOFs, thus resulted in the order of activation capacities: Fe(Nic) > Fe(PyBDC) > Fe(PIP). It was demonstrated that the activation of persulfate was mainly ascribed to the heterogeneous process that accomplished by surface-bounded Fe(II) acted as the main active site to provided electrons for persulfate or dissolved oxygen. EPR and molecular probe studies confirmed the coexistence of SO4·-, ·OH, and O2·-, and differentiated their contributions in SMX degradation. Possible degradation pathways of SMX were proposed based on the detection results of intermediates by UPLC-MS/MS. This work provides a new prospect into the synthesis of high-performance MOFs with strong electron-donating properties as efficient persulfate activators, which may encourage the employ of MOFs in the wastewater treatment process.

14.
Angiogenesis ; 22(4): 477-479, 2019 11.
Artículo en Inglés | MEDLINE | ID: mdl-31250326

RESUMEN

We present the case of an old woman with ALK-rearranged stage IV lung adenocarcinoma who received crizotinib. She presented with severe dyspnea on the 34th day, and diffuse ground-glass opacifications in her chest. A diagnosis of crizotinib-induced ILD was confirmed. Corticosteroids were administered. However, the disease was still progressing rapidly. Therefore, as a monoclonal antibody against vascular endothelial growth factor, bevacizumab was administered in low doses (200 mg on days one and three). Her symptoms began to improve. Our clinical experience indicates that bevacizumab combined with corticosteroids might be a promising treatment in crizotinib-induced ILD patients.


Asunto(s)
Adenocarcinoma del Pulmón/tratamiento farmacológico , Corticoesteroides/administración & dosificación , Bevacizumab/administración & dosificación , Crizotinib , Enfermedades Pulmonares Intersticiales , Neoplasias Pulmonares/tratamiento farmacológico , Adenocarcinoma del Pulmón/patología , Crizotinib/administración & dosificación , Crizotinib/efectos adversos , Femenino , Humanos , Enfermedades Pulmonares Intersticiales/inducido químicamente , Enfermedades Pulmonares Intersticiales/tratamiento farmacológico , Enfermedades Pulmonares Intersticiales/patología , Neoplasias Pulmonares/patología , Persona de Mediana Edad
15.
Cancer Cell Int ; 19: 318, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31798347

RESUMEN

BACKGROUND: This study aimed to investigate the prognostic value of the potential biomarker collagen triple helix repeat containing 1 (CTHRC1) in lung adenocarcinoma (LUAD) patients. METHODS: A total of 210 LUAD patients diagnosed between 2003 and 2016 in the Department of Pathology of the First Affiliated Hospital of Sun Yat-sen University were included in this study. The expression of CTHRC1 and vascular endothelial growth factor (VEGF), and microvessel density (MVD, determined by CD34 immunostaining) were evaluated by immunohistochemistry in LUAD tissues. The association between the expression of these proteins and clinicopathological features or clinical outcomes was analyzed. RESULTS: Here, we confirmed that CTHRC1 expression was associated with prognosis and can serve as a significant predictor for overall survival (OS) and progression-free survival (PFS) in LUAD. Additionally, we observed that CTHRC1 expression was positively associated with tumor angiogenesis markers, such as VEGF expression (P < 0.001) and MVD (P < 0.01). Then, we performed gene set enrichment analysis (GESA) and cell experiments to confirm that enhanced CTHRC1 expression can promote VEGF levels. Based on and cox regression analysis, a predictive model that included CTHRC1, VEGF and MVD was constructed and confirmed as a more accurate independent predictor for OS (P = 0.001) and PFS (P < 0.001) in LUAD than other parameters. CONCLUSIONS: These results demonstrated that high CTHRC1 expression may be closely related to tumor angiogenesis and poor prognosis in LUAD. The predictive model based on the CTHRC1 level and tumor angiogenesis markers can be used to predict LUAD patient prognosis more accurately.

16.
J Environ Sci (China) ; 85: 129-137, 2019 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-31471019

RESUMEN

Benzotriazole UV stabilizers (BT-UVs) have attracted concerns due to their ubiquitous occurrence in the aquatic environment, and their bioaccumulative and toxic properties. However, little is known about their aquatic environmental degradation behavior. In this study, photodegradation of a representative of BT-UVs, 2-(2-hydroxy-5-methylphenyl)benzotriazole (UV-P), was investigated under simulated sunlight irradiation. Results show that UV-P photodegrades slower under neutral conditions (neutral form) than under acidic or alkaline conditions (cationic and anionic forms). Indirect photodegradation is a dominant elimination pathway of UV-P in coastal seawaters. Dissolved organic matter (DOM) from seawaters accelerate the photodegradation rates mainly through excited triplet DOM (3DOM⁎), and the roles of singlet oxygen and hydroxyl radical are negligible in the matrixes. DOM from seawaters impacted by mariculture exhibits higher steady-state concentration of 3DOM⁎ ([3DOM⁎]) relative to those from pristine seawaters, leading to higher photosensitizing effects on the photodegradation. Halide ions inhibit the DOM-sensitized photodegradation of UV-P by decreasing [3DOM⁎]. Photodegradation half-lives of UV-P are estimated to range from 24.38 to 49.66 hr in field water bodies of the Yellow River estuary. These results are of importance for assessing environmental fate and risk UV-P in coastal water bodies.


Asunto(s)
Protectores Solares/química , Triazoles/química , Contaminantes Químicos del Agua/química , Fotólisis , Agua de Mar
17.
Immunology ; 155(2): 238-250, 2018 10.
Artículo en Inglés | MEDLINE | ID: mdl-29791021

RESUMEN

Recently, bi-functional molecules that can redirect immune effectors to tumour cells have emerged as potentially robust mediators of tumour regression in clinical trials. Two modalities in particular, bi-specific antibodies for T-cell redirection and activation (BiTe) and immune-mobilizing monoclonal T-cell receptors against cancer (ImmTAC), are being evaluated in efficacy studies as 'off-the-shelf' reagents. Optimal therapy will require an understanding and means to address regulatory mechanisms of limiting efficacy. In light of this, we evaluated the impact of induced regulatory T (iTreg) cells on the efficacy of tumour cell killing redirected by ImmTAC and demonstrated down-regulation of T-cell proliferation and expression of CD25, CD107a, Granzyme B and Perforin by ImmTAC-redirected T cells. Significant recovery of ImmTAC potency, however, could be achieved when combined with an anti-programmed cell death protein 1 monoclonal antibody. Furthermore, we found that among lung cancer patients failing to respond to ImmTAC therapy, there was a significantly higher fraction of Treg cells in the peripheral blood mononuclear cells of lung cancer patients than in healthy donors. These results provide in vitro evidence for an iTreg cell-mediated immunosuppression of ImmTAC-redirected T-cell responses. Whilst immune checkpoint blockade can reverse the Treg cell suppression, it forms a rational basis for a combination of the blockade with ImmTAC in clinical trials.


Asunto(s)
Anticuerpos Monoclonales/farmacología , Citotoxicidad Inmunológica , Terapia de Inmunosupresión , Activación de Linfocitos/inmunología , Receptor de Muerte Celular Programada 1/antagonistas & inhibidores , Linfocitos T Reguladores/inmunología , Linfocitos T Reguladores/metabolismo , Citometría de Flujo , Humanos , Neoplasias/inmunología , Neoplasias/metabolismo , Neoplasias/patología , Neoplasias/terapia , Subgrupos de Linfocitos T/inmunología , Subgrupos de Linfocitos T/metabolismo , Linfocitos T Citotóxicos/inmunología , Linfocitos T Citotóxicos/metabolismo
18.
Environ Sci Technol ; 52(18): 10490-10499, 2018 09 18.
Artículo en Inglés | MEDLINE | ID: mdl-30141914

RESUMEN

Novel brominated flame retardants (NBFRs) have become ubiquitous emerging organic pollutants. However, little is known about their transformation in natural waters. In this study, aquatic photochemical behavior of a representative NBFR, 2,3-dibromopropyl-2,4,6-tribromophenyl ether (DPTE), was investigated by simulated sunlight irradiation experiment. Results show that DPTE can undergo direct photolysis (apparent quantum yield 0.008 ± 0.001) and hydroxyl radical (·OH) initiated oxidation (second order reaction rate constant 2.4 × 109 M-1·s-1). Dissolved organic matter (DOM) promotes the photodegradation due to generation of excited triplet DOM and ·OH. Two chlorinated intermediates were identified in the photodegradation of DPTE in seawaters. Density functional theory calculation showed that ·Cl or ·Cl2- addition reactions on C-Br sites of the phenyl group and H-abstraction reactions from the propyl group are main reaction pathways of DPTE with the chlorine radicals. The ·Cl or ·Cl2- addition proceeds via a replacement mechanism to form chlorinated intermediates. Environmental half-lives of DPTE relevant with photodegradation are estimated to be 6.5-1153.9 days in waters of the Yellow River estuarine region. This study provides valuable insights into the phototransformation behavior of DPTE in natural waters, which is helpful for persistence assessment of the NBFRs.


Asunto(s)
Retardadores de Llama , Hidrocarburos Bromados , Contaminantes Químicos del Agua , Éter , Fotólisis
19.
Mol Carcinog ; 56(11): 2391-2399, 2017 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-28418088

RESUMEN

Phosphorylation of Pyruvate Kinase M2 (PKM2) on Tyr105 by fibroblast growth factor receptor 1 (FGFR1) has been shown to promote its nuclear localization as well as cell growth in lung cancer. Better understanding the regulation of this process would benefit the clinical treatment for lung cancer. Here, it has been found that the adaptor protein receptor for activated PKC kinase (RACK1) formed a complex with FGFR1 and PKM2, and activated the FGFR1/PKM2 signaling. Knocking down the expression of RACK1 impaired the phosphorylation on Tyr105 of PKM2 and inhibited the growth and migration of lung cancer cells, while over-expression of RACK1 in lung cancer cells led to the resistance to Erdafitinib. Moreover, knocking down the expression of RACK1 impaired the tumorigenesis of lung cancer driven by LKB loss and mutated Ras (KrasG12D). Taken together, our study demonstrated the pivotal roles of RACK1 in FGFR1/PKM2 signaling, suggesting FGFR1/RACK1/PKM2 might be a therapeutic target for lung cancer treatment.


Asunto(s)
Carcinoma de Células Escamosas/metabolismo , Proteínas Portadoras/metabolismo , Proteínas de Unión al GTP/metabolismo , Neoplasias Pulmonares/metabolismo , Pulmón/patología , Proteínas de la Membrana/metabolismo , Proteínas de Neoplasias/metabolismo , Mapas de Interacción de Proteínas , Receptor Tipo 1 de Factor de Crecimiento de Fibroblastos/metabolismo , Receptores de Superficie Celular/metabolismo , Hormonas Tiroideas/metabolismo , Animales , Carcinoma de Células Escamosas/patología , Proteínas Portadoras/análisis , Línea Celular Tumoral , Movimiento Celular , Proliferación Celular , Proteínas de Unión al GTP/análisis , Humanos , Pulmón/metabolismo , Neoplasias Pulmonares/patología , Proteínas de la Membrana/análisis , Ratones , Proteínas de Neoplasias/análisis , Receptor Tipo 1 de Factor de Crecimiento de Fibroblastos/análisis , Receptores de Cinasa C Activada , Receptores de Superficie Celular/análisis , Hormonas Tiroideas/análisis , Proteínas de Unión a Hormona Tiroide
20.
J Gastroenterol Hepatol ; 32(12): 1966-1974, 2017 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-28370348

RESUMEN

BACKGROUND AND AIM: Epithelial-mesenchymal transition (EMT), characterized by the decrease of E-cadherin (E-Cad) and increase in vimentin and alpha-smooth muscle actin (α-SMA), was demonstrated to participate in inflammatory bowel disease-related fibrosis. miR-200b plays an anti-fibrosis role in inhibiting EMT by targeting ZEB1 and ZEB2. But the stability of exogenous miR-200b in blood limits its application. Microvesicles (MVs), which can transfer miRNAs among cells and prevent them from degradation, may provide an excellent transport system for the delivery of miR-200b in the treatment of fibrosis. METHODS: Bone marrow mesenchymal stem cells (BMSCs) were transfected with lentivirus to overexpress miR-200b. The MVs packaged with miRNA-200b were harvested for the anti-fibrotic treatment using in vitro (transforming growth factor beta 1-mediated EMT in intestinal epithelial cells: IEC-6) and in vivo (TNBS-induced intestinal fibrosis in rats) models. The pathological morphology was observed, and the fibrosis related proteins, such as E-Cad, vimentin, α-SMA, ZEB1, and ZEB2, were detected. RESULTS: MiR-200b-MVs would significantly reverse the morphology in TGF-ß1-treated IEC-6 cells and improve the TNBS-induced colon fibrosis histologically. The treatment of miR-200b-MVs increased miR-200b levels both in the IEC-6 cells and colon, resulting in a significant prevention EMT and alleviation of fibrosis. The expression of E-Cad was increased, and the expressions of vimentin and α-SMA were decreased. ZBE1 and ZEB2, the targets of miR-200b, were also decreased. CONCLUSIONS: miR-200b could be transferred from genetically modified BMSCs to the target cells or tissue by MVs. The mechanisms of miR-200b-MVs in inhibiting colonic fibrosis were related to suppressing the development of EMT by targeting ZEB1and ZEB2.


Asunto(s)
Micropartículas Derivadas de Células , Colitis/tratamiento farmacológico , Colitis/fisiopatología , Transición Epitelial-Mesenquimal/efectos de los fármacos , Intestinos/patología , MicroARNs/administración & dosificación , MicroARNs/fisiología , Actinas/metabolismo , Animales , Cadherinas/metabolismo , Células Cultivadas , Colitis/patología , Modelos Animales de Enfermedad , Sistemas de Liberación de Medicamentos , Transición Epitelial-Mesenquimal/genética , Fibrosis , Proteínas de Homeodominio , Mucosa Intestinal/metabolismo , Masculino , MicroARNs/metabolismo , MicroARNs/farmacología , Terapia Molecular Dirigida , Ratas Sprague-Dawley , Factores de Transcripción , Vimentina/metabolismo , Homeobox 1 de Unión a la E-Box con Dedos de Zinc
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA